Skip to main content
Journal cover image

Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.

Publication ,  Journal Article
Butler, J; Hernandez, AF; Anstrom, KJ; Kalogeropoulos, A; Redfield, MM; Konstam, MA; Tang, WHW; Felker, GM; Shah, MR; Braunwald, E
Published in: JACC Heart Fail
September 2016

Although therapy with mineralocorticoid receptor antagonists (MRAs) is recommended for patients with chronic heart failure (HF) with reduced ejection fraction and in post-infarction HF, it has not been studied well in acute HF (AHF) despite being commonly used in this setting. At high doses, MRA therapy in AHF may relieve congestion through its natriuretic properties and mitigate the effects of adverse neurohormonal activation associated with intravenous loop diuretics. The ATHENA-HF (Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure) trial is a randomized, double-blind, placebo-controlled study of the safety and efficacy of 100 mg/day spironolactone versus placebo (or continued low-dose spironolactone use in participants who are already receiving spironolactone at baseline) in 360 patients hospitalized for AHF. Patients are randomized within 24 h of receiving the first dose of intravenous diuretics. The primary objective is to determine if high-dose spironolactone, compared with standard care, will lead to greater reductions in N-terminal pro-B-type natriuretic peptide levels from randomization to 96 h. The secondary endpoints include changes in the clinical congestion score, dyspnea relief, urine output, weight change, loop diuretic dose, and in-hospital worsening HF. Index hospital length of stay and 30-day clinical outcomes will be assessed. Safety endpoints include risk of hyperkalemia and renal function. Differences among patients with reduced versus preserved ejection fraction will be determined. (Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure [ATHENA-HF]; NCT02235077).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JACC Heart Fail

DOI

EISSN

2213-1787

Publication Date

September 2016

Volume

4

Issue

9

Start / End Page

726 / 735

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Spironolactone
  • Sodium Potassium Chloride Symporter Inhibitors
  • Peptide Fragments
  • Patient Readmission
  • Natriuretic Peptide, Brain
  • Mortality
  • Mineralocorticoid Receptor Antagonists
  • Hyperkalemia
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Butler, J., Hernandez, A. F., Anstrom, K. J., Kalogeropoulos, A., Redfield, M. M., Konstam, M. A., … Braunwald, E. (2016). Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. JACC Heart Fail, 4(9), 726–735. https://doi.org/10.1016/j.jchf.2016.06.003
Butler, Javed, Adrian F. Hernandez, Kevin J. Anstrom, Andreas Kalogeropoulos, Margaret M. Redfield, Marvin A. Konstam, WH Wilson Tang, G Michael Felker, Monica R. Shah, and Eugene Braunwald. “Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.JACC Heart Fail 4, no. 9 (September 2016): 726–35. https://doi.org/10.1016/j.jchf.2016.06.003.
Butler J, Hernandez AF, Anstrom KJ, Kalogeropoulos A, Redfield MM, Konstam MA, et al. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. JACC Heart Fail. 2016 Sep;4(9):726–35.
Butler, Javed, et al. “Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.JACC Heart Fail, vol. 4, no. 9, Sept. 2016, pp. 726–35. Pubmed, doi:10.1016/j.jchf.2016.06.003.
Butler J, Hernandez AF, Anstrom KJ, Kalogeropoulos A, Redfield MM, Konstam MA, Tang WHW, Felker GM, Shah MR, Braunwald E. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. JACC Heart Fail. 2016 Sep;4(9):726–735.
Journal cover image

Published In

JACC Heart Fail

DOI

EISSN

2213-1787

Publication Date

September 2016

Volume

4

Issue

9

Start / End Page

726 / 735

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Spironolactone
  • Sodium Potassium Chloride Symporter Inhibitors
  • Peptide Fragments
  • Patient Readmission
  • Natriuretic Peptide, Brain
  • Mortality
  • Mineralocorticoid Receptor Antagonists
  • Hyperkalemia
  • Humans